Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 35Recurrence 27Multiple Myeloma 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 25Lymphoma 20Neoplasms 16Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 15Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Mantle-Cell 13Leukemia 13Carcinoma, Non-Small-Cell Lung 13Stomach Neoplasms 11Ovarian Neoplasms 9Pancreatic Neoplasms 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Myelodysplastic Syndromes 6Melanoma 6Lymphoma, B-Cell, Marginal Zone 6Breast Neoplasms 6Liposarcoma, Myxoid 5Colorectal Neoplasms 5Burkitt Lymphoma 5

Interventions

fludarabine 1efgartigimod alfa 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × fludarabine × Clear all
NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Gilead Sciences

Phase 1 Recruiting
52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡